Global tumor ablation market is expected to reach USD 4,225.84 Million by 2030 from USD 1,506.85 Million in 2022, growing at a CAGR of 13.8% during the forecast period of 2023 to 2030.
Market Segmentation:
Global Tumor Ablation Market, By Type (Thermal Ablation and Chemical Ablation), Types of Treatment (Percutaneous, Laparoscopic, and Surgical), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Liver Cancer, Kidney Cancer, Bone Cancer, and Others), End Users (Hospitals, Oncology Centers, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Rest of Asia Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, U.A.E., Egypt, Israel, Rest of Middle East and Africa)- Industry Trends and Forecast to 2030.
Overview of Global Tumor Ablation Market Dynamics :
- Driver
- Increasing prevalence of cancer globally
- Restraint
- Regulatory hurdles for approval
- Opportunity
- Favourable reimbursement scenario
Market Players:
Some of the key players operating in the global tumor ablation market are:
- Boston Scientific Corporation
- Medtronic
- Olympus
- Stryker
- Biotronik
- AngioDynamics
- Bioventus LLC.
- BVM Medical Limited
- EDAP TMS
- Ethicon, Inc.
- HealthTronics, Inc.
- IceCure Medical
- Insightec
- Integra LifeSciences
- Merit Medical Systems
- Sonablate Corp.
- Terumo Europe NV
TABLE OF CONTENTS
1 INTRODUCTION 36
- 1.1 OBJECTIVES OF THE STUDY 36
- 1.2 MARKET DEFINITION 36
- 1.3 OVERVIEW OF THE GLOBAL TUMOR ABLATION MARKET 36
- 1.4 CURRENCY AND PRICING 38
- 1.5 LIMITATIONS 38
- 1.6 MARKETS COVERED 38
2 MARKET SEGMENTATION 41
- 2.1 MARKETS COVERED 41
- 2.2 GEOGRAPHICAL SCOPE 42
- 2.3 YEARS CONSIDERED FOR THE STUDY 43
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 44
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47
- 2.6 MULTIVARIATE MODELLING 48
- 2.7 TYPE SEGMENT LIFELINE CURVE 49
- 2.8 MARKET END USERS COVERAGE GRID 50
- 2.9 DBMR MARKET POSITION GRID 51
- 2.10 VENDOR SHARE ANALYSIS 52
- 2.11 SECONDARY SOURCES 53
- 2.12 ASSUMPTIONS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 56
- 4.1 PESTEL ANALYSIS 59
- 4.2 PORTER'S FIVE FORCES MODEL 60
5 REGULATORY FRAMEWORK 61
- 5.1 REGULATORY SCENARIO IN THE U.S 61
- 5.2 REGULATORY SCENARIO IN GERMANY 62
- 5.3 REGULATORY SCENARIO IN CHINA 62
- 5.4 REGULATORY SCENARIO IN AUSTRALIA 63
- 5.5 REGULATORY SCENARIO IN BRAZIL 63
- 5.6 REGULATORY SCENARIO IN SAUDI ARABIA 64
6 MARKET OVERVIEW 65
- 6.1 DRIVERS 67
- 6.1.1 RISING PREVALENCE OF CANCER GLOBALLY 67
- 6.1.2 INCREASING INCLINATION OF SURGEONS AND PATIENTS TOWARD MINIMALLY INVASIVE PROCEDURES 67
- 6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 68
- 6.1.4 INCREASING AWARENESS AND EDUCATION 68
- 6.2 RESTRAINTS 69
- 6.2.1 REGULATORY HURDLES FOR APPROVAL 69
- 6.2.2 LIMITED CLINICAL EVIDENCE 69
- 6.3 OPPORTUNITIES 70
- 6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 70
- 6.3.2 STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 70
- 6.4 CHALLENGES 71
- 6.4.1 TECHNICAL CHALLENGES IN TARGETING THE TUMOR 71
- 6.4.2 COMPETITION FROM ALTERNATIVE TREATMENT MODALITIES 71
7 GLOBAL TUMOR ABLATION MARKET, BY TYPE 72
- 7.1 OVERVIEW 73
- 7.2 THERMAL ABLATION 76
- 7.2.1 TUMOR ABLATION SYSTEMS 77
- 7.2.1.1 RADIOFREQUENCY 78
- 7.2.1.1.1 BIPOLAR 78
- 7.2.1.1.2 MULTIPOLAR 78
- 7.2.2 IMAGE GUIDANCE PRODUCTS AND ACCESSORIES 78
- 7.2.2.1 CT 79
- 7.2.2.2 MR IMAGING 79
- 7.2.2.3 FLUOROSCOPY 79
- 7.2.2.4 OTHERS 79
- 7.2.2.5 MICROWAVE 79
- 7.2.2.6 CRYOABLATION 79
- 7.2.2.7 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) 79
- 7.2.2.8 LASER 79
- 7.3 CHEMICAL ABLATION 79
- 7.3.1 ETHANOL 80
- 7.3.2 ACETIC ACID 80
8 GLOBAL TUMOR ABLATION MARKET, BY TYPES OF TREATMENT 81
- 8.1 OVERVIEW 82
- 8.2 PERCUTANEOUS 85
- 8.2.1 BREAST CANCER 86
- 8.2.2 LUNG CANCER 86
- 8.2.3 PROSTATE CANCER 86
- 8.2.4 LIVER CANCER 86
- 8.2.5 KIDNEY CANCER 86
- 8.2.6 OTHER CANCERS 86
- 8.3 LAPAROSCOPY 86
- 8.3.1 BREAST CANCER 87
- 8.3.2 LUNG CANCER 87
- 8.3.3 PROSTATE CANCER 87
- 8.3.4 LIVER CANCER 87
- 8.3.5 KIDNEY CANCER 88
- 8.3.6 OTHER CANCERS 88
- 8.4 SURGICAL 88
- 8.4.1 BREAST CANCER 89
- 8.4.2 LUNG CANCER 89
- 8.4.3 PROSTATE CANCER 89
- 8.4.4 LIVER CANCER 89
- 8.4.5 KIDNEY CANCER 89
- 8.4.6 OTHER CANCERS 89
9 GLOBAL TUMOR ABLATION MARKET, BY CANCER TYPE 90
- 9.1 OVERVIEW 91
- 9.2 BREAST CANCER 94
- 9.3 LUNG CANCER 94
- 9.4 PROSTATE CANCER 95
- 9.5 LIVER CANCER 96
- 9.6 KIDNEY CANCER 97
- 9.7 BONE CANCER 98
- 9.8 OTHERS 99
10 GLOBAL TUMOR ABLATION MARKET, BY END USERS 100
- 10.1 OVERVIEW 101
- 10.2 HOSPITALS 104
- 10.3 ONCOLOGY CENTERS 104
- 10.4 OTHERS 105
11 GLOBAL TUMOR ABLATION MARKET, BY DISTRIBUTION CHANNEL 106
- 11.1 OVERVIEW 107
- 11.2 DIRECT TENDER 110
- 11.3 RETAIL SALES 110
12 GLOBAL TUMOR ABLATION MARKET, BY REGION 112
- 12.1 OVERVIEW 113
- 12.2 NORTH AMERICA 118
- 12.2.1 U.S. 127
- 12.2.2 CANADA 132
- 12.2.3 MEXICO 137
- 12.3 EUROPE 142
- 12.3.1 GERMANY 152
- 12.3.2 U.K. 157
- 12.3.3 FRANCE 162
- 12.3.4 ITALY 167
- 12.3.5 RUSSIA 172
- 12.3.6 SPAIN 177
- 12.3.7 NETHERLANDS 182
- 12.3.8 SWITZERLAND 187
- 12.3.9 BELGIUM 192
- 12.3.10 TURKEY 197
- 12.3.11 REST OF EUROPE 202
- 12.4 ASIA PACIFIC 203
- 12.4.1 CHINA 213
- 12.4.2 JAPAN 218
- 12.4.3 INDIA 223
- 12.4.4 AUSTRALIA 228
- 12.4.5 SOUTH KOREA 233
- 12.4.6 INDONESIA 238
- 12.4.7 PHILIPPINES 243
- 12.4.8 THAILAND 248
- 12.4.9 MALAYSIA 253
- 12.4.10 SINGAPORE 258
- 12.4.11 REST OF ASIA-PACIFIC 263
- 12.5 SOUTH AMERICA 264
- 12.5.1 BRAZIL 273
- 12.5.2 ARGENTINA 278
- 12.5.3 REST OF SOUTH AMERICA 283
- 12.6 MIDDLE EAST AND AFRICA 284
- 12.6.1 SAUDI ARABIA 293
- 12.6.2 SOUTH AFRICA 298
- 12.6.3 U.A.E. 303
- 12.6.4 EGYPT 308
- 12.6.5 ISRAEL 313
- 12.6.6 REST OF MIDDLE EAST AND AFRICA 318
13 GLOBAL TUMOR ABLATION MARKET, COMPANY LANDSCAPE 319
- 13.1 COMPANY SHARE ANALYSIS: GLOBAL 319
- 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 320
- 13.3 COMPANY SHARE ANALYSIS: EUROPE 321
- 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 322
14 SWOT ANALYSIS 323
15 COMPANY PROFILE 324
- 15.1 BOSTON SCIENTIFIC CORPORATION 324
- 15.1.1 COMPANY SNAPSHOT 324
- 15.1.2 REVENUE ANALYSIS 324
- 15.1.3 COMPANY SHARE ANALYSIS 325
- 15.1.4 PRODUCT PORTFOLIO 325
- 15.1.5 RECENT DEVELOPMENT 325
- 15.2 MEDTRONIC 326
- 15.2.1 COMPANY SNAPSHOT 326
- 15.2.2 REVENUE ANALYSIS 326
- 15.2.3 COMPANY SHARE ANALYSIS 327
- 15.2.4 PRODUCT PORTFOLIO 327
- 15.2.5 RECENT DEVELOPMENT 327
- 15.3 OLYMPUS 328
- 15.3.1 COMPANY SNAPSHOT 328
- 15.3.2 REVENUE ANALYSIS 328
- 15.3.3 COMPANY SHARE ANALYSIS 329
- 15.3.4 PRODUCT PORTFOLIO 329
- 15.3.5 RECENT DEVELOPMENT 329
- 15.4 STRYKER 330
- 15.4.1 COMPANY SNAPSHOT 330
- 15.4.2 REVENUE ANALYSIS 330
- 15.4.3 COMPANY SHARE ANALYSIS 331
- 15.4.4 PRODUCT PORTFOLIO 331
- 15.4.5 RECENT DEVELOPMENT 331
- 15.5 BIOTRONIK 332
- 15.5.1 COMPANY SNAPSHOT 332
- 15.5.2 COMPANY SHARE ANALYSIS 332
- 15.5.3 PRODUCT PORTFOLIO 333
- 15.5.4 RECENT DEVELOPMENT 333
- 15.6 ANGIODYNAMICS. 334
- 15.6.1 COMPANY SNAPSHOT 334
- 15.6.2 REVENUE ANALYSIS 334
- 15.6.3 PRODUCT PORTFOLIO 335
- 15.6.4 RECENT DEVELOPMENT 335
- 15.7 BIOVENTUS LLC. 336
- 15.7.1 COMPANY SNAPSHOT 336
- 15.7.2 PRODUCT PORTFOLIO 336
- 15.7.3 RECENT DEVELOPMENT 336
- 15.8 BVM MEDICAL LIMITED 337
- 15.8.1 COMPANY SNAPSHOT 337
- 15.8.2 PRODUCT PORTFOLIO 337
- 15.8.3 RECENT DEVELOPMENT 337
- 15.9 EDAP TMS 338
- 15.9.1 COMPANY SNAPSHOT 338
- 15.9.2 REVENUE ANALYSIS 338
- 15.9.3 PRODUCT PORTFOLIO 339
- 15.9.4 RECENT DEVELOPMENT 339
- 15.10 ETHICON, INC. 340
- 15.10.1 COMPANY SNAPSHOT 340
- 15.10.2 PRODUCT PORTFOLIO 340
- 15.10.3 RECENT DEVELOPMENT 340
- 15.11 HEALTHTRONICS, INC. 341
- 15.11.1 COMPANY SNAPSHOT 341
- 15.11.2 PRODUCT PORTFOLIO 341
- 15.11.3 RECENT DEVELOPMENT 341
- 15.12 ICECURE MEDICAL 342
- 15.12.1 COMPANY SNAPSHOT 342
- 15.12.2 REVENUE ANALYSIS 342
- 15.12.3 PRODUCT PORTFOLIO 343
- 15.12.4 RECENT DEVELOPMENT 343
- 15.13 INSIGHTEC. 344
- 15.13.1 COMPANY SNAPSHOT 344
- 15.13.2 PRODUCT PORTFOLIO 344
- 15.13.3 RECENT DEVELOPMENT 344
- 15.14 INTEGRA LIFESCIENCES 345
- 15.14.1 COMPANY SNAPSHOT 345
- 15.14.2 REVENUE ANALYSIS 345
- 15.14.3 PRODUCT PORTFOLIO 346
- 15.14.4 RECENT DEVELOPMENT 346
- 15.15 MERIT MEDICAL SYSTEMS. 347
- 15.15.1 COMPANY SNAPSHOT 347
- 15.15.2 REVENUE ANALYSIS 347
- 15.15.3 PRODUCT PORTFOLIO 348
- 15.15.4 RECENT DEVELOPMENT 348
- 15.16 SONABLATE CORP. 349
- 15.16.1 COMPANY SNAPSHOT 349
- 15.16.2 PRODUCT PORTFOLIO 349
- 15.16.3 RECENT DEVELOPMENT 349
- 15.17 TERUMO EUROPE NV 350
- 15.17.1 COMPANY SNAPSHOT 350
- 15.17.2 PRODUCT PORTFOLIO 350
- 15.17.3 RECENT DEVELOPMENT 350
16 QUESTIONNAIRE 351
17 RELATED REPORTS 354